Request Demo
Last update 03 May 2025
Salmeterol xinafoate/Tiotropium Bromide Hydrate
Last update 03 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Tiotropium bromide/salmeterol |
Action antagonists, agonists |
Mechanism M3 receptor antagonists(Muscarinic acetylcholine receptor M3 antagonists), β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC19H24BrNO5S2 |
InChIKeyMQLXPRBEAHBZTK-SEINRUQRSA-M |
CAS Registry411207-31-3 |
View All Structures (2)
Related
5
Clinical Trials associated with Salmeterol xinafoate/Tiotropium Bromide HydrateNCT00673478
A Randomised, Open-label, 4-way Crossover Study to Characterize the Pharmacokinetics, Safety and Efficacy of FDC Tiotropium/Salmeterol, Tiotropium, Salmeterol and a Free Combination of Tiotropium Plus Salmeterol Following 4-week Treatment Periods in Patients With COPD.
NCT00662740
1-yr Study Comparing TioSal Combo Regimens Versus Single Agent Therapies (Spiriva HandiHaler and Salmeterol PE Capsule)
NCT00668772
1-yr Study Comparing TioSal Combo Regimens Versus Single Agent Therapies (Spiriva HandiHaler and Salmeterol PE Capsule)
100 Clinical Results associated with Salmeterol xinafoate/Tiotropium Bromide Hydrate
Login to view more data
100 Translational Medicine associated with Salmeterol xinafoate/Tiotropium Bromide Hydrate
Login to view more data
100 Patents (Medical) associated with Salmeterol xinafoate/Tiotropium Bromide Hydrate
Login to view more data
100 Deals associated with Salmeterol xinafoate/Tiotropium Bromide Hydrate
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pulmonary Disease, Chronic Obstructive | Phase 3 | United States | 15 Apr 2008 | |
| Pulmonary Disease, Chronic Obstructive | Phase 3 | Austria | 15 Apr 2008 | |
| Pulmonary Disease, Chronic Obstructive | Phase 3 | Belgium | 15 Apr 2008 | |
| Pulmonary Disease, Chronic Obstructive | Phase 3 | Canada | 15 Apr 2008 | |
| Pulmonary Disease, Chronic Obstructive | Phase 3 | Denmark | 15 Apr 2008 | |
| Pulmonary Disease, Chronic Obstructive | Phase 3 | Estonia | 15 Apr 2008 | |
| Pulmonary Disease, Chronic Obstructive | Phase 3 | Finland | 15 Apr 2008 | |
| Pulmonary Disease, Chronic Obstructive | Phase 3 | France | 15 Apr 2008 | |
| Pulmonary Disease, Chronic Obstructive | Phase 3 | Germany | 15 Apr 2008 | |
| Pulmonary Disease, Chronic Obstructive | Phase 3 | Greece | 15 Apr 2008 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free